Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Capital Expenditures (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Capital Expenditures for 14 consecutive years, with $26000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 74.76% to $26000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48000.0 through Dec 2025, down 57.89% year-over-year, with the annual reading at $29000.0 for FY2024, N/A changed from the prior year.
  • Capital Expenditures hit $26000.0 in Q4 2025 for Vistagen Therapeutics, down from $95000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $200400.0 in Q3 2021 to a low of -$200300.0 in Q1 2022.
  • Historically, Capital Expenditures has averaged $20905.9 across 5 years, with a median of $25500.0 in 2021.
  • Biggest five-year swings in Capital Expenditures: tumbled 199400.0% in 2022 and later skyrocketed 472.22% in 2024.
  • Year by year, Capital Expenditures stood at -$100.0 in 2021, then crashed by 199400.0% to -$199500.0 in 2022, then soared by 109.02% to $18000.0 in 2023, then surged by 472.22% to $103000.0 in 2024, then crashed by 74.76% to $26000.0 in 2025.
  • Business Quant data shows Capital Expenditures for VTGN at $26000.0 in Q4 2025, $95000.0 in Q3 2025, and $30000.0 in Q2 2025.